
    
      Since around 50 patients were included in Spanish centers involved in the Phase III Tygacil
      clinical development program, and on the basis of the recruitment capacity of the centers
      within the predefined time window and the number of patients consenting to be enrolled in the
      study, the total number of patients estimated to be enrolled in the study is 500. With this
      sample size, it will be possible to obtain precise estimations of the incidence of particular
      types of adverse events.
    
  